Literature DB >> 20046782

Spectrophotometric determination of certain benzimidazole proton pump inhibitors.

A A Syed1, Ayesha Syeda.   

Abstract

Spectrophotometric method for the determination of certain proton pump inhibitors belonging to the benzimidazole class of compounds has been developed. The method is based on the reaction of omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole with iron (III) and subsequent reaction with ferricyanide under neutral condition which yields Prussian blue product with maximum absorption at 720-730 nm. The commonly encountered excipients and additives that often accompany pharmaceutical preparations did not interfere with the determination. The method was applied for the determination of omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole in pharmaceutical preparations and no difference was found statistically. Thus, the spectrophotometric method can be applied as inexpensive, rapid, easy, accurate and precise method for the routine analysis of the five proton pump inhibitors in pharmaceutical preparations.

Entities:  

Keywords:  Benzimidazole; proton pump inhibitors; prussian blue; spectrophotometry

Year:  2008        PMID: 20046782      PMCID: PMC2792556          DOI: 10.4103/0250-474X.44605

Source DB:  PubMed          Journal:  Indian J Pharm Sci        ISSN: 0250-474X            Impact factor:   0.975


Omeprazole (OMZ), lansoprazole (LNZ), pantoprazole (PNZ), rabeprazole (RBZ) and esomeprazole (EMZ) belong to a class of antisecretory compounds. These compounds are acid labile and reversibly transformed in acidic medium to a sulfonamide1. They are referred to as proton pump inhibitors (PPIs) and were introduced for the management of duodenal ulcer, gastric ulcer or pathogenic hypersecretory condition2. Gastric PPIs are prodrugs that require an acid- induced activation. It is a weak base that is converted to its active form by gastric acid before acting on the proton pump. It inhibits gastric acid secretion by covalently binding to the proton pump (H+/K+ATPase)3. Development of new methods capable of determining drug concentrations in pharmaceutical formulations is important. Contemporary analytical methodologies adopted to determine antiulcer drugs in different matrices include electroanalytical techniques4–8, chromatographic methods 9–14 and automated methods such as flow injection analysis1516. However, these methods are deficient with respect to specificity, sensitivity, simplicity and short time analysis. A survey of literature revealed that no data has been published on the UV-visible spectrophotometric methods for RBZ and EMZ and very limited methods are available for the spectrophotometric determination of OMZ, LNZ and PNZ in formulations. The details of existing spectrophotometric reagents and their spectral characteristics are enumerated in Table 1.
TABLE 1

COMPARISON OF VISIBLE SPECTROPHOTOMETRIC METHODS FOR THE DETERMINATION OF ANTIULCER DRUGS

ReagentColoured speciesDrugs analyzedλmax nmRange μg ml-1RemarksRef
Iron(III)radical cationPNZ45530–300Heating at 60° for 30 min17
Iron(III)radical cationOMZ41115–95Heating at 65±5° for 15 min17
Chromium(III)radical cationOMZ33910–60Heating at 65±5° for 10 min17
Cobalt(II)radical cationOMZ52315–150Heating at 65±5° for 35 min17
2,3-dichloro-5, 6-dicyano-1, 4-benzoquinonecharge transfer complexLNZ, PNZ45710–90, 10-60Reaction carried out in acetonitrile medium18
Iodinecharge transfer complexLNZ, PNZ293, 3591.5.6.7, 17.7.141.6Reaction carried out in chloroform medium18
Eosin and copper(II)molecular complexLNZ, PNZ5493.7.16.6, 4.3.25.9Heating at 60° for 20 min, heating at 70° for 25 min18
MBTHcoupled productOMZ6601.0.10.0Stable only for 20 min19
m-aminophenolcoupled productOMZ4202.0–32Stable only for 10 min19
Proposed methodcomplexOMZ, LNZ, PNZ, RBZ, EMZ720–7300.2-4.0Reaction carried out at room temperature and stable for 3 h-

OMZ is omeprazole; LNZ is lansoprazole; PNZ is pantoprazole; RBZ is rabeprazole; EMZ is esomeprazole, Ref denotes reference

COMPARISON OF VISIBLE SPECTROPHOTOMETRIC METHODS FOR THE DETERMINATION OF ANTIULCER DRUGS OMZ is omeprazole; LNZ is lansoprazole; PNZ is pantoprazole; RBZ is rabeprazole; EMZ is esomeprazole, Ref denotes reference An attempt was made to develop simple, sensitive and selective spectrophotometric procedure for the determination of OMZ, LNZ, PNZ, RBZ and EMZ in both preformulations and dosage forms. The proposed procedure involves the reduction of iron(III) to iron(II) which subsequently reacts with ferricyanide to form a Prussian blue product in neutral medium having maximum absorption at 720–730 nm. This method has distinct advantages of sensitivity and stability and also does not require heating or distillation and exhibits reliability due to reproducibility. UV/Vis spectrophotometer Uvidec-610 type with 1.0-cm matched cell (Jasco, Tokyo, Japan) was employed for measuring the absorbance values. Omeprazole, lansoprazole, pantoprazole, rabeprazole from Cipla, India and commercial tablets of esomeprazole, ferric chloride and potassium ferricyanide (BDH, India) were used. All other chemicals and solvents used were of analytical grade. Double distilled water was used throughout. Samples of the drugs (100 mg) were dissolved in about 10.0 ml alcohol and made up to 100-ml in a volumetric flask with distilled water and stored in a refrigerator. Standard solutions of the drugs were prepared every day by diluting the stock solution with distilled water. Aqueous solution of 0.0025 M ferric chloride containing few drops of 5 M hydrochloric acid and 0.001 M potassium ferricyanide was prepared in double distilled water. Aliquots of standard solutions of OMZ (2.0–70.0 μg), LNZ (5.0–90.0 μg), PNZ (5.0–100.0 μg), RBZ (5.0–80.0 μg) and EMZ (5.0–80.0 μg) were transferred into 25–ml calibrated flask. Ferric chloride and potassium ferricyanide each 3.0 ml were added to each flask, the contents were mixed well and kept aside for 20 min at 27°. It was diluted to the mark with distilled water. The absorbance was measured at 720–730 nm against the corresponding reagent blank and calibration graphs were constructed. The optical characteristics of the chromogen are presented in Table 2.
TABLE 2

OPTICAL CHARACTERISTICS OF THE CHROMOGEN USING IRON(III) IN THE PRESENCE OF FERRICYANIDE

OMZLNZPNZRBZEMZ
ColourBlueBlueBlueBlueBlue
λmax (nm)720730720720725
Stability (h)3.02.53.02.53.0
Beer’s law (ng/ml)80–2800200–3600200–4000200–3200200–3200
Molar absorptivity (L mol-1cm-1)8.76×1046.78×1046.74×1046.44×1047.22×104
Sandell’s sensitivity (μg cm-2)0.0040.0050.0060.0050.005
Regression equation*
Slope (a)0.17020.13880.10690.12010.1120
Intercept (b)0.05230.04110.0691-0.06100.0141
Correlation coefficient0.98530.99250.98440.99210.9899

y= ax+b where x is the concentration of OMZ, LNZ, PNZ, RBZ or EMZ in μg/ml, OMZ is omeprazole; LNZ is lansoprazole; PNZ is pantoprazole; RBZ is rabeprazole; EMZ is esomeprazole

OPTICAL CHARACTERISTICS OF THE CHROMOGEN USING IRON(III) IN THE PRESENCE OF FERRICYANIDE y= ax+b where x is the concentration of OMZ, LNZ, PNZ, RBZ or EMZ in μg/ml, OMZ is omeprazole; LNZ is lansoprazole; PNZ is pantoprazole; RBZ is rabeprazole; EMZ is esomeprazole Twenty capsules each of OMZ and LNZ were emptied carefully and the mass of the collected contents was determined. The capsule contents were finely powdered in a mortar. In case of PNZ, RBZ and EMZ twenty tablets each were finely powdered. An accurately weighed 50 mg of the powdered drug was dissolved in about 10.0 ml of alcohol and filtered through a Whatman No. 42 filter paper. The filtrate was made up to 100-ml with distilled water in a volumetric flask. A suitable volume of the filtrate was accurately diluted with water to obtain a sample concentration of 10 μg/ml. An aliquot of this solution was treated as per the procedure described earlier for the determination of antiulcer drugs. The method for determination of antiulcer drugs involves the reaction of the drugs with ferric salt, in the presence of potassium ferricyanide under neutral condition, to produce a Prussian blue coloured product with maximum absorption at 720–730 nm. The reaction involves the reduction of iron(III) by omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole to form iron(II), which subsequently reacts with ferricyanide to give a Prussian blue (PB) product in neutral medium. The factors affecting the colour development such as reproducibility, sensitivity and adherence to Beer’s law were investigated using omeprazole as a model compound, since the other antiulcer drugs behaved similar to it. A blue coloured product with maximum absorption at 720 nm was formed when omeprazole was allowed to react with ferric chloride, in presence of potassium ferricyanide in neutral medium. It was found that a 0.0025 M solution of ferric chloride in the range of 2.0-5.0 ml and 0.001 M solution of potassium ferricyanide in the range of 1.0-4.0 ml were necessary to achieve maximum colour intensity and stability of the blue colour. Hence, 3.0 ml each of ferric chloride and ferricyanide solutions were recommended. The order of addition of ferric chloride, ferricyanide and drug solution for the formation of the blue complex was studied. No appreciable change in the absorbance or colour of the product was observed when the order of addition of these reactants was altered. Table 2 shows the linear calibration ranges and equation parameters for this procedure. Separate determinations at different concentrations of each drug gave a coefficient of variation not exceeding 2%. The resultant product of the proposed method was studied at different temperatures. The coloured product was stable up to 3 h at room temperature. Various additives and excipients that often accompany antiulcer drugs in pharmaceutical preparations such as lactose, glucose, starch, gum acacia, magnesium stearate and talc did not interfere, while vitamin C was found to interfere significantly. The applicability of the method to assay pharmaceutical preparations was examined. Commercial capsules/tablets containing OMZ, LNZ, PNZ, RBZ and EMZ were successfully analyzed by the proposed method. The results obtained are listed in Table 3. The results were compared statistically using F- and t- tests. The calculated F- and t- values did not exceed the theoretical values. Therefore, it is concluded that there is no significant difference in the proposed method of analysis with respect to repeatability (F-test) and accuracy (t-test).
TABLE 3

DETERMINATION OF CERTAIN PROTON PUMP INHIBITORS IN COMMERCIAL SAMPLES BY THE PROPOSED METHOD

DrugLabel claim (mg per drug)*Recovery% ±SD**Additional analyte added (mg)*Recovery% ±SD**Reported method found%
Omelac capsule (Omeprazole)2098.1±1.11 (n=5)20100.2±0.8497.2±1.09 [17] (n=5)
Lanpro capsule (Lansoprazole)1599.8±0.25 (n=5)1599.8±0.6099.63±0.11 [18] (n=5)
Pan tablet (Pantoprazole)2099.0±1.20 (n=4)2099.0±1.0298.5±0.61 [17] (n=4)
Rabeloc tablet (Rabeprazole)2099.0±0.72 (n=7)20100.8±0.7298.4±0.44 [20] (n=7)
Raciper tablet (Esomeprazole)2099.1±0.922099.4±0.92-

Proposed method

standard deviation

DETERMINATION OF CERTAIN PROTON PUMP INHIBITORS IN COMMERCIAL SAMPLES BY THE PROPOSED METHOD Proposed method standard deviation The procedure described here is simple, rapid, sensitive, selective and cost effective. It is evident from the results that the recommended procedure is well suited for the assay and evaluation of drugs, in preformulation and dosage forms. It can be applied for direct determination of proton pump inhibitors in drug control laboratories.
  15 in total

1.  High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.

Authors:  H Katsuki; A Hamada; C Nakamura; K Arimori; M Nakano
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-06-05

2.  Determination of lansoprazole in pharmaceutical capsules by flow injection analysis using UV-detection.

Authors:  Duygu Yeniceli; Dilek Dogrukol-Ak; Muzaffer Tuncel
Journal:  J Pharm Biomed Anal       Date:  2004-09-21       Impact factor: 3.935

3.  Experimental design in the development of voltammetric method for the assay of omeprazole.

Authors:  S Pinzauti; P Gratteri; S Furlanetto; P Mura; E Dreassi; R Phan-Tan-Luu
Journal:  J Pharm Biomed Anal       Date:  1996-06       Impact factor: 3.935

4.  High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism.

Authors:  T Andersson; P O Lagerstrøm; J O Miners; M E Veronese; L Weidolf; D J Birkett
Journal:  J Chromatogr       Date:  1993-09-22

5.  Determination of omeprazole in human plasma by high-performance liquid chromatography.

Authors:  J Macek; P Ptácek; J Klíma
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-02-07

6.  The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.

Authors:  M Morii; H Takata; H Fujisaki; N Takeguchi
Journal:  Biochem Pharmacol       Date:  1990-02-15       Impact factor: 5.858

7.  Spectrophotometric methods for the determination of lansoprazole and pantoprazole sodium sesquihydrate.

Authors:  A A Moustafa
Journal:  J Pharm Biomed Anal       Date:  2000-02       Impact factor: 3.935

8.  Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column.

Authors:  B D Landes; G Miscoria; B Flouvat
Journal:  J Chromatogr       Date:  1992-05-20

9.  Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.

Authors:  A Radi; N Abd El-Ghany; T Wahdan
Journal:  Farmaco       Date:  2004-07

10.  Spectrophotometric methods for the determination of omeprazole in bulk form and pharmaceutical formulations.

Authors:  C S Sastry; P Y Naidu; S S Murty
Journal:  Talanta       Date:  1997-07       Impact factor: 6.057

View more
  1 in total

1.  Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.

Authors:  Yinhe Tan; Xiaoqing Si; Lulu Zhong; Xin Feng; Xinmin Yang; Min Huang; Chuanbin Wu
Journal:  Drug Dev Ind Pharm       Date:  2016-04-11       Impact factor: 3.225

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.